Document ID: chunk:federal_register_of_legislation:F2023L00941:reg:9:p3
Version: federal_register_of_legislation:F2023L00941
Segment Type: reg
Provision Reference: reg 9 (pt 3/6)
Character Range: 10050–12999

peripheral neuropathy;
(23)      taking a drug from the specified list of drugs that cannot be ceased or substituted, at the time of the clinical onset of peripheral neuropathy;
Note: specified list of drugs that cannot be ceased or substituted is defined in the Schedule 1 - Dictionary.
(24)      taking a drug that cannot be ceased or substituted and which is associated in the individual with the clinical onset of peripheral neuropathy during drug therapy and either:
(a)          the improvement of peripheral neuropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the redevelopment of peripheral neuropathy on rechallenge with the same drug or another drug from the same class of drugs; and
where the drug was being taken at the time of the clinical onset of peripheral neuropathy;
(25)      taking a drug from the specified list of drugs at the time of the clinical onset of peripheral neuropathy;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(26)      taking a drug which is associated in the individual with the clinical onset of peripheral neuropathy during drug therapy and either:
(a)          the improvement of peripheral neuropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the redevelopment of peripheral neuropathy on rechallenge with the same drug or another drug from the same class of drugs; and
where the drug was being taken at the time of the clinical onset of peripheral neuropathy;
(27)      being treated with cisplatin within the 6 months before the clinical onset of peripheral neuropathy;
(28)      having bariatric surgery within the 5 years before the clinical onset of peripheral neuropathy;
Note: bariatric surgery is defined in the Schedule 1 - Dictionary.
(29)      having vitamin B6 (pyridoxine) hypervitaminosis at the time of the clinical onset of peripheral neuropathy;
Note: vitamin B6 (pyridoxine) hypervitaminosis is defined in the Schedule 1 - Dictionary.
(30)      undergoing stem cell or bone marrow transplantation before the clinical onset of peripheral neuropathy;
(31)      having acute carbon monoxide poisoning, with a carboxyhaemoglobin level of over 20 percent, within the 30 days before the clinical onset of peripheral neuropathy;
(32)      having amyloidosis at the time of the clinical worsening of peripheral neuropathy;
Note: amyloidosis is defined in the Schedule 1 - Dictionary.
(33)      having chronic liver disease at the time of the clinical worsening of peripheral neuropathy;
(34)      having chronic renal failure at the time of the clinical worsening of peripheral neuropathy;
Note: chronic renal failure is defined in the Schedule 1 - Dictionary.
(35)      having sarcoidosis at the time of the clinical worsening of peripheral neuropathy;
(36)      having an endocrine disease from the specified list of endocrine diseases at the time of the clinical worsening of peripheral neuropathy;